Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NICE Rejects J&J’s Blood Cancer Drug

By Drug Discovery Trends Editor | March 3, 2016

Johnson & Johnson (J&J) received a rejection from the United Kingdom’s National Institute of Care and Excellence (NICE) regarding its new leukemia drug Imbruvica. 

NICE’s job is to decide which drugs should be covered under health insurance plans in England and Wales. Draft guidance issued by the agency said it wasn’t confident Imbruvica “represented an effective use of resources,” according to Reuters. It has a list price of $78,000 a year or 55,954.50 pounds

Imbruvica has shown promise in treating three different types of blood cancer, but NICE felt this medication wasn’t a viable treatment option for chronic lymphocytic leukemia (CLL) patients who would not be good candidates for chemo-immunotherapy, reported FiercePharma.

J&J’s European supplier Janssen released a statement expressing their dismay at this decision. The company was “extremely disappointed” because 48 countries have accepted the drug under the CLL indication.

Janssen said it will work with NICE to find a way to ensure patients continue to have access to Imbruvica. FiercePharma elaborated that Imbruvica is a top-seller for Janssen. It brought in $235 million in the fourth quarter of 2015 versus $92 million in the previous year.

WATCH: Clinton Campaign Ad Criticizes Valeant Pharmaceuticals


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE